Literature DB >> 31334885

No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis.

Salman Hussain1, Ambrish Singh2, Saima Zameer1, Mohammad Chand Jamali3, Harveen Baxi4, Syed Obaidur Rahman1, Mahtab Alam4, Mohammad Altamish4, Avinash Kumar Singh1, Dasari Anil5, Md Sarfaraj Hussain6, Adil Ahmad7, Abul Kalam Najmi4.   

Abstract

BACKGROUND AND AIM: A growing body of literature suggests the association between dementia risk and proton pump inhibitor (PPI) use. Therefore, we aimed to investigate the association between PPI use and dementia risk.
METHODS: An extensive literature search was performed in PubMed, Embase, and Cochrane till March 31, 2019. All the studies (cohort and case-control) assessing the association between PPI use and dementia risk were eligible for inclusion. Articles were selected based on the screening of title and abstract, data were extracted, and risk of bias was assessed using Newcastle-Ottawa scale. The primary outcome was pooled risk of dementia among PPI user as compared with non-PPI user. Secondary outcomes include dementia risk based on subgroups. Statistical analysis was performed using review manager software.
RESULTS: Twelve studies (eight cohort and four case-control) were found to be eligible for inclusion. Majority of the studies were of high quality. Dementia was diagnosed based on International Classification of Diseases 9/10 codes in majority of the included studies. PPI use was not associated with the dementia risk, with a pooled relative risk (RR) of 1.05 (95% confidence interval [CI]: 0.96-1.15), P = 0.31. Subgroup analysis based on study design (cohort: P = 0.14; case-control: P = 0.14), sex (RR 1.25 [95% CI: 0.97-1.60], P = 0.08), histamine 2 receptor antagonist blockers (P = 0.93), and Alzheimer's disease (RR 1.00 [95% CI: 0.91-1.09], P = 0.93) revealed no significant association between PPI use and dementia risk.
CONCLUSION: We found no significant association between PPI use and the risk of dementia or Alzheimer's disease.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Alzheimer's disease; PPI; dementia; meta-analysis, omeprazole

Year:  2019        PMID: 31334885     DOI: 10.1111/jgh.14789

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  Promoting Successful Cognitive Aging: A Ten-Year Update.

Authors:  Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 2.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Authors:  Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

3.  Binding of omeprazole to protein targets identified by monoclonal antibodies.

Authors:  Naw May Pearl Cartee; Michael M Wang
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

4.  Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias.

Authors:  Francisco Torres-Bondia; Farida Dakterzada; Leonardo Galván; Miquel Buti; Gaston Besanson; Eric Gill; Roman Buil; Jordi de Batlle; Gerard Piñol-Ripoll
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

5.  Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis.

Authors:  Salman Hussain; Ambrish Singh; Benny Antony; Jitka Klugarová; M Hassan Murad; Aarthi S Jayraj; Alena Langaufová; Miloslav Klugar
Journal:  J Clin Med       Date:  2022-08-10       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.